Title: 0703 - Long Term Hydrolytic Stability of Hybrid Ceramics
Rasha Alamoush (Presenter)
University of Manchester
Julian Satterthwaite, University of Manchester
Nick Silikas, The University of Manchester
Objectives: Objectives: The aim of this study was to assess water sorption of novel CAD/CAM Hybrid Ceramics compared to CAD/CAM ceramic after 8 months of storage in water and artificial saliva.
Methods: Seven materials with different filler loading were tested: Four nano ceramic composite block (Lava Ultimate (LU), Shofu (SH), Cersmart (CS), Brilliant Crios (BC)); One polymer infiltrated ceramic network ceramic block (Enamic, EN); One ceramic filled Poly ether ether ketone (Dentokeep, DK); and one feldspathic ceramic block (Vitabloc Mark II, VM). 98 samples were prepared with 14×12×1 mm dimensions. All specimens were highly polished and cleaned in an ultrasonic water bath. Samples of each material (n=7) were randomly immersed in 10 ml of water or artificial saliva, stored at 37°C and weighed at different time intervals. Data were analysed using one-way ANOVA, and Tukey’s post hoc test (α=0.05).
Results: All materials reached a stable mass within six to eight months in both storage media. Sorption values in water and Artificial saliva for all materials were not significantly different. Water Sorption values (Table 1) in water ranged from -1.21 (0.4) μg/mm3 to 39.3 (2.1) μg/mm3 and in Artificial saliva ranged from -0.7 (0.2) μg/mm3 to 41.6 (1.3) μg/mm3. Mass Percentage change of the tested materials in water ranged from 0.02% to 2.2% and in artificial saliva ranged from 0.04% to 2.25%.
Conclusions: Novel hybrid-ceramics were hydrolytically stable, though not as stable as a ceramic material. Water sorption of CAD/CAM composite blocks are material-dependent and are affected by the filler weight percentage. Water and Artificial saliva have comparable effects as storage media in terms of water sorption.
|Material tested||Water sorption in Artificial saliva (μg/mm3)||Water sorption in Water (μg/mm3)|
|VM||-0.70 (0.20)a||-1.21 (0.40)a|
|EN||15.49 (0.70)b||15.77 (0.60)b|
|LU||36.03 (1.40)c||34.79 (0.42)c|
|BC||21.58 (0.46)d||21.75 (0.42)d|
|CS||26.47 (0.91)e||24.54 (1.28)e|
|SH||41.61 (1.33)f||39.31 (0.90)f|
|DK||5.19 (0.44)g||5.09 (0.60)g|
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE